Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes
✍ Scribed by Susanna A. Möller; Ralph A. Reisfeld
- Publisher
- Springer-Verlag
- Year
- 1991
- Tongue
- English
- Weight
- 948 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0340-7004
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
T lymphocytes of 8 patients with ovarian cancer were targeted to the tumor cells using F(ab')2 fragments of a bispecific monoclonal antibody (bsAb), specific for CD3 (a component of the T lymphocyte receptor for antigen) and for the folate receptor MOv I 8 (overexpressed by ovarian carcinoma cells)
Recently we reported that cytotoxic T-cell clones can be retar eted to unrelated tumor cells by bispecific monoclonal antbodies (MAbs), anti-CDJ and anti-ovarian carcinoma (cuOCl TR) (Mezzanzanica eta/., 1988). In the perspective of in vivo tumor immunotherapy, as an alternative to cytotoxic T lymph
The specificity and efficiency of tumor-cell lysis by the retargeting of murine cytolytic lymphocytes (CTL) with bispecific antibodies was examined. Bispecific antibodies (also known as heteroaggregated or hybrid antibodies) were produced by the chemical coupling of monoclonal antibodies (MAbs) agai
We investigated the role of the LFA-I /ICAM, VLA-4/VCAM-I and CD2/LFAJ adhesion pathways in the cytolysis of tumor cells mediated by an anti-EGF-R/anti-CD3 bispecific monoclonal antibody (biMAb). The biMAb induced efficient lysis of